Study on Correlation Between Homocyseteine and Matrix Meta11oproteinase-9 of Coronary Heart Disease Patient
|School||Ningxia Medical University|
|Keywords||Coronary heart disease Acute coronary syndrome Stable angina pectoris Homocysteine Matrix metalloproteinase-9|
Objective To observe the patients with coronary heart disease (CHD) in serum homocysteine ??(homocysteine, Hcy) levels, the simultaneous detection of matrix metalloproteinase -9 (matrix metallopoeinases-9, MMP-9), and evaluate the Hcy, MMP-9 and coronary the relationship between the severity and plaque vulnerability and observation the Hcy, MMP-9 both explore in the pathogenesis of CHD, the possible role of the development for the prevention and treatment of clinical CHD provide the appropriate information. To observe the group selected from February 2009 to August 2009, the Second Affiliated Hospital of Ningxia Medical University of Cardiology initial diagnosis of CHD, diagnosed CHD hospitalization of 62 patients with coronary angiography (CAG) in parallel. First of all, according to the clinical conditions of patients with CHD, the severity of the disease, the observation group was divided into 40 patients with stable angina pectoris (SA) 22 cases of acute coronary syndrome group (ACS); according to the results of CAG, the observation group was divided into a lesions of 19 patients, lesions group of 20 patients, 2 and 3 lesions in 23 cases, a total of three subgroups; selected control group to line healthy 28 cases over the same period in the Second Affiliated Hospital of Ningxia Medical University. Each group were compared between serum Hcy, MMP-9 level whether the differences, to explore the relationship of Hcy and MMP-9, and the results of the correlation analysis. (1) comparison between the ACS group, SA group and control group: serum Hcy levels were 23.68 ± 8.15μmol / L, 17.62 ± 4.45μmol / L, of 13.50 ± 1.86μmol / L; serum MMP-9 levels were 1279.70 ± 555.53 ng / mL, 711.45 ± 343.56ng/mL, 338.93 ± 181.55ng/mL; ACS group, serum Hcy SA group, MMP-9 water were significantly higher than those in the control group (P lt; 0.05); ACS group serum Hcy, MMP -9 levels were significantly higher than the SA group (P lt; 0.05). (2) 3-vessel group, the comparison between the two lesions, a disease group and control group: serum Hcy levels, respectively, 25.93 ± 6.69μmol / L, 21.01 ± 8.57μmol / L, (17.41 ± 4.62μmol) / L, 13.50 ± the 1.86μmol / l; serum MMP-9 level 1444.22 ± 625.29ng/mL, a 1052.60 ± 339.71ng/mL, 637.72 ± 301.20 ng / mL, 338.93 ± 181.55ng/mL; 3-vessel disease group, two lesions a lesion group serum Hcy, MMP-9 water were significantly higher than those in the control group (P lt; 0.05); 3-vessel disease group, two lesions serum Hcy, MMP-9 water average higher than a disease group (P lt ; 0.05); 3 lesions serum Hcy than two lesions (P lt; 0.05), MMP-9 level. (3) CHD patients with serum homocysteine ??and MMP-9 was positively correlated (r = 0.351, P lt; 0.05) Conclusion (1) serum Hcy, MMP-9 level to a certain extent reflect the condition of patients with CHD serious, can be used as serum markers determine atherosclerotic plaque vulnerability, provide the basis for clinical predictors of the occurrence of ACS. (2) With the expansion of the scope of coronary artery disease, serum Hcy level of MMP-9 of gradually increased. Serum Hcy, MMP-9 levels and the severity of coronary artery disease are closely related. (3) CHD patients with serum Hcy and serum MMP-9 was significantly positively related to the combined detection of the two can help clinicians to understand the disease and guide treatment, to assess the efficacy provide an objective basis. (4) elevated serum Hcy levels can induce the expression of MMP-9, caused by an imbalance of the reorganization and degradation of extracellular matrix, involved in the occurrence of CHD development.